Apex Bioscience Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1993)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2001
NCT00021502
First Marketed Drug
2016
cyproheptadine (periactin)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

APEX GmbH | Apex Labs Ltd. | Apex Medical Research - Illinois | APEX PHARMS INC | Apex Research Institute, Santa Ana, CA 92705

Active Ingredients

Marketed Drugs (1)

cyproheptadine (periactin) (2016)

Drugs in Phase 3 Trials (2)

hemoglobin (1 trial)

paroxetine (paxil) (1 trial)

Drugs in Phase 2 Trials (3)

psilocybin (1 trial)

sitagliptin (januvia) (1 trial)

tecovirimat (tpoxx) (1 trial)

Drugs in Phase 1 Trials (2)

azd-5672 (1 trial)

pacritinib (Vonjo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hot Flashes (Phase 3)

Primary Myelofibrosis (Phase 1)

Renal Insufficiency (Phase 1)

Shock (Phase 3)

Syndrome (Phase 3)

Systemic Inflammatory Response Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 7